{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:12:51Z","timestamp":1790903571803,"version":"4.1.0"},"reference-count":53,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15607","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:25:36Z","timestamp":1776687936000},"page":"1-15","source":"Crossref","is-referenced-by-count":1,"title":["Clinical features and outcomes of peripheral T\u2011cell lymphoma, not otherwise specified: A single institution retrospective analysis of 30 cases"],"prefix":"10.3892","volume":"31","author":[{"given":"Meng-Xue","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Haematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Medical, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Na","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Haematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Haematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukai","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Haematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"key20260514105742_b1-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"key20260514105742_b2-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States","volume":"34","author":"Adams","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20260514105742_b3-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"key20260514105742_b4-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s12185-018-2404-8","article-title":"Current status and progress of lymphoma management in China","volume":"107","author":"Shi","year":"2018","journal-title":"Int J Hematol"},{"key":"key20260514105742_b5-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"key":"key20260514105742_b6-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the international peripheral T-cell lymphoma project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"key20260514105742_b7-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-319-99716-2_4","article-title":"Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)","volume":"176","author":"Oluwasanjo","year":"2019","journal-title":"Cancer Treat Res"},{"key":"key20260514105742_b8-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.3390\/cancers13184535","article-title":"Peripheral T-cell lymphoma, not otherwise specified: Clinical manifestations, diagnosis, and future treatment","volume":"13","author":"Pileri","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20260514105742_b9-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"S889","DOI":"10.1182\/blood-2025-889","article-title":"Early time-to-relapse as a predictor of survival in mature T-cell\/NK-cell lymphomas: Results from the PETAL consortium","volume":"146","author":"Sorial","year":"2025","journal-title":"Blood"},{"key":"key20260514105742_b10-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"key":"key20260514105742_b11-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"334","DOI":"10.2174\/0113892029301904240513045755","article-title":"Deciphering the genetic complexity of classical hodgkin lymphoma: Insights and effective strategies","volume":"25","author":"Lee","year":"2024","journal-title":"Curr Genomics"},{"key":"key20260514105742_b12-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2174\/0109298665398122250929045705","article-title":"PLEKHG7 expression: A biomarker for prognosis and targeted therapy in diffuse large B-cell lymphoma","volume":"32","author":"Lyu","year":"2025","journal-title":"Protein Pept Lett"},{"key":"key20260514105742_b13-ol-31-6-15607","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"key":"key20260514105742_b14-ol-31-6-15607","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"key20260514105742_b15-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"key20260514105742_b16-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"key20260514105742_b17-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"NCCN Clinical Practice Guidelines in Oncology. T-Cell Lymphomas, Version 2.2022","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260514105742_b18-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s44178-023-00063-8","article-title":"China Anti-Cancer Association (CACA) guidelines for holistic integrative management of lymphoma (version 2022)","volume":"2","author":"Zhang","year":"2023","journal-title":"Holist Integ Oncol"},{"key":"key20260514105742_b19-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"key20260514105742_b20-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20260514105742_b21-ol-31-6-15607","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S.","year":"2017"},{"key":"key20260514105742_b22-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jfma.2023.07.014","article-title":"Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients","volume":"123","author":"Chen","year":"2024","journal-title":"J Formos Med Assoc"},{"key":"key20260514105742_b23-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"key20260514105742_b24-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"21770","DOI":"10.1002\/cam4.6743","article-title":"Impact of primary organ site of involvement by peripheral T-cell lymphoma not otherwise specified on survival","volume":"12","author":"Davis","year":"2023","journal-title":"Cancer Med"},{"key":"key20260514105742_b25-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41379-022-01022-w","article-title":"Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations","volume":"35","author":"Nicolae","year":"2022","journal-title":"Mod Pathol"},{"key":"key20260514105742_b26-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/blood.2021015019","article-title":"DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS","volume":"140","author":"Herek","year":"2022","journal-title":"Blood"},{"key":"key20260514105742_b27-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"key20260514105742_b28-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"key20260514105742_b29-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1097\/01.pas.0000173238.17331.6b","article-title":"Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified","volume":"29","author":"Asano","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"key20260514105742_b30-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2559.2012.04199.x","article-title":"Nodal cytotoxic molecule (CM)-positive Epstein-Barr virus (EBV)-associated peripheral T cell lymphoma (PTCL): A clinicopathological study of 26 cases","volume":"61","author":"Kato","year":"2012","journal-title":"Histopathology"},{"key":"key20260514105742_b31-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20260514105742_b32-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdq359","article-title":"Comparison of four prognostic scores in peripheral T-cell lymphoma","volume":"22","author":"Guti\u00e9rrez-Garc\u00eda","year":"2011","journal-title":"Ann Oncol"},{"key":"key20260514105742_b33-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"112191","DOI":"10.1016\/j.nut.2023.112191","article-title":"Superiority of CRP-albumin-lymphocyte index as a prognostic biomarker for patients with gastric cancer","volume":"116","author":"Zhang","year":"2023","journal-title":"Nutrition"},{"key":"key20260514105742_b34-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/carcin\/bgu247","article-title":"Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer","volume":"36","author":"Liu","year":"2015","journal-title":"Carcinogenesis"},{"key":"key20260514105742_b35-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cllc.2021.12.010","article-title":"Serum albumin: Early prognostic marker of benefit for immune checkpoint inhibitor monotherapy but not chemoimmunotherapy","volume":"23","author":"Guo","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"key20260514105742_b36-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjh.15258","article-title":"Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the international T cell project network","volume":"181","author":"Federico","year":"2018","journal-title":"Br J Haematol"},{"key":"key20260514105742_b37-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12185-017-2362-6","article-title":"A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas","volume":"107","author":"Kaito","year":"2018","journal-title":"Int J Hematol"},{"key":"key20260514105742_b38-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1111\/ajco.13831","article-title":"The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients","volume":"19","author":"Chen","year":"2023","journal-title":"Asia Pac J Clin Oncol"},{"key":"key20260514105742_b39-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00277-023-05536-4","article-title":"25-Hydroxy vitamin D deficiency is an inferior predictor of peripheral T-cell lymphomas","volume":"103","author":"Shen","year":"2024","journal-title":"Ann Hematol"},{"key":"key20260514105742_b40-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat Med"},{"key":"key20260514105742_b41-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers12010019","article-title":"STAT3 activation and oncogenesis in lymphoma","volume":"12","author":"Zhu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20260514105742_b42-ol-31-6-15607","first-page":"2824","article-title":"Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms","volume":"141","author":"Jaeger","year":"2023","journal-title":"Blood"},{"key":"key20260514105742_b43-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20260514105742_b44-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish lymphoma registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"key20260514105742_b45-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"835103","DOI":"10.3389\/fimmu.2022.835103","article-title":"Comparison of chemotherapy combined with chidamide versus chemotherapy in the frontline treatment for peripheral T-cell lymphoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"key20260514105742_b46-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"key20260514105742_b47-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3390\/cancers17071137","article-title":"Retreatment with brentuximab vedotin in patients with relapsed\/refractory CD30+ malignancies: A retrospective medical chart review study in Spain-The BELIEVE study","volume":"17","author":"Sureda","year":"2025","journal-title":"Cancers (Basel)"},{"key":"key20260514105742_b48-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: A population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"key":"key20260514105742_b49-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"key20260514105742_b50-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1080\/10428194.2025.2545927","article-title":"Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives","volume":"66","author":"Meeuwes","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"key20260514105742_b51-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00277-016-2877-6","article-title":"Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified","volume":"96","author":"Qi","year":"2017","journal-title":"Ann Hematol"},{"key":"key20260514105742_b52-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00277-013-1738-9","article-title":"DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: A retrospective evaluation of parallel patient cohorts of one center","volume":"92","author":"Mikesch","year":"2013","journal-title":"Ann Hematol"},{"key":"key20260514105742_b53-ol-31-6-15607","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:57:50Z","timestamp":1778745470000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,4,20]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15607","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}